When Antidepressants Cause Visual Disturbances: The Medication Differential FND Cannot Afford to Ignore
Visual snow, blurred vision, persistent afterimages, light sensitivity and difficulties seeing in low light are among the visual disturbances discussed in connection with Functional Neurological Disorder (FND). On neurosymptoms.org, visual snow and several other visual presentations appear within the broader discussion of functional visual symptoms. But what happens when published pharmacological research identifies some of these same disturbances in patients taking antidepressants, including patients whose symptoms persist after the medication has been discontinued?
That question emerged following our earlier examination, Functional Visual Symptoms: When Blurred Vision, Photophobia and Visual Snow Become FND. A reader, @recover2renew, drew our attention to research published by David Healy, Dee Mangin and Jonathan Lochhead concerning visual adverse effects associated with serotonin reuptake-inhibiting antidepressants. Their work provides a particularly relevant addition to the differential diagnosis discussion because it examines visual disturbances that overlap with those described in functional neurological presentations.
What initially appeared to be a useful 2022 reference becomes even more interesting when the subsequent literature is considered. A further study, published online in November 2025 and appearing in the May 2026 issue of the International Journal of Risk & Safety in Medicine, specifically investigated whether serotonin reuptake-inhibiting antidepressants might trigger visual snow syndrome. Together, these publications raise a question that deserves serious attention: how thoroughly are medication-related adverse effects investigated before visual disturbances are attributed to FND?
The 2022 Study: Visual Problems Associated With Antidepressants
In 2022, David Healy, Dee Mangin and ophthalmologist Jonathan Lochhead published Development and persistence of patient-reported visual problems associated with serotonin reuptake inhibiting antidepressants. The study examined spontaneous adverse-event reports concerning medications that inhibit serotonin reuptake, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs) and certain tricyclic antidepressants.
The researchers investigated a range of reported visual disturbances rather than restricting their attention to familiar ocular adverse effects. These included visual snow, difficulties with night vision, palinopsia and other changes in visual perception. Importantly, some patients described symptoms continuing after discontinuation of the suspected medication. The reports raised concerns about visual adverse effects that might not be adequately captured by conventional assumptions about antidepressant safety.
The distinction between association and causation remains important. Spontaneous adverse-event reports are useful for identifying potential safety signals, particularly unusual or persistent problems that may not have been recognised in clinical trials. However, they cannot independently establish how frequently an adverse effect occurs or prove that the suspected medication caused every reported symptom. The study nevertheless establishes that these visual disturbances have been sufficiently concerning to warrant systematic pharmacovigilance investigation.
This is directly relevant to the functional visual symptoms discussion. A patient presenting with persistent visual snow or afterimages may have a history of antidepressant exposure that deserves consideration. The fact that a symptom can be described within an FND framework does not eliminate the possibility of a medication-related contribution.
The 2026 Study: A More Specific Investigation of Visual Snow
The subsequent study, Serotonin reuptake inhibiting antidepressants: A trigger for visual snow syndrome?, was authored by Hannaa Bobat, David Healy, Dee Mangin and Jonathan Lochhead. Published online on 7 November 2025 and included in the May 2026 journal issue, it examined spontaneous adverse-event reports specifically involving visual snow and visual snow syndrome associated with serotonin reuptake-inhibiting antidepressants.
The researchers identified 24 cases involving patients from eight countries and ten different medications. All 24 patients reported visual snow, while ten, approximately 42%, met the study's classification for visual snow syndrome. Symptoms reportedly began during medication use in 14 cases, following dose reduction in six cases and after discontinuation in four cases.
| Reported finding | 2026 study |
|---|---|
| Total cases | 24 |
| Visual snow syndrome | 10 patients (42%) |
| Onset during medication use | 14 patients (58%) |
| Onset after dose reduction | 6 patients (25%) |
| Onset after discontinuation | 4 patients (17%) |
| Stopped suspected medication without symptom resolution at reporting | 22 patients (92%) |
The persistence finding is particularly notable. At the time of reporting, 22 of the 24 patients had discontinued the suspected medication without resolution of their visual symptoms. This does not establish that antidepressants caused permanent neurological injury, nor does it provide a population-level estimate of persistent adverse effects. It does, however, challenge the assumption that a medication-related explanation becomes irrelevant simply because the patient is no longer taking the drug.
The researchers concluded that serotonin reuptake-inhibiting antidepressants may trigger visual snow or visual snow syndrome, including presentations that persist, worsen or emerge after stopping treatment. Their findings remain subject to the limitations of retrospective spontaneous reporting, including selection bias, incomplete clinical information and uncertainty about causality. The 24 cases cannot establish incidence or determine how often similar symptoms have other explanations.
Nevertheless, the clinical implication is difficult to dismiss: current and previous medication exposure may be relevant when investigating persistent visual disturbances. A clinician who considers only medications being taken at the time of examination may miss an important part of the patient's history.
A Citalopram Case With Normal Investigations
The concern is not restricted to the RxISK database. In a case report published in the European Journal of Clinical Pharmacology, Ozan Eren and colleagues described a 31-year-old woman who developed visual snow syndrome approximately two weeks after starting citalopram 20 mg for postpartum depression.
Her reported symptoms included black and white dots across the visual field, intermittent flashes, entoptic phenomena, visual disturbances described as swirls, photophobia and increased sensitivity to external sensory stimuli. She had a history of episodic migraine without aura, but the visual presentation developed following initiation of citalopram.
Of particular interest, neurological and ophthalmological examinations, visual evoked potentials and brain MRI were unremarkable. Despite these findings, the authors considered a possible adverse drug reaction, supported by a structured causality assessment. The visual snow syndrome persisted after citalopram was discontinued.
This case illustrates an important diagnostic limitation. Normal routine investigations do not establish that a visual disturbance is functional. They may help exclude particular structural or ophthalmological abnormalities, but they cannot independently determine the cause of every disturbance in visual processing. The case authors did not prove that citalopram caused the syndrome, and their causality assessment classified the relationship as possible. Nevertheless, the medication history and temporal relationship were considered clinically meaningful rather than dismissed because conventional investigations were normal.
That distinction becomes especially important when compared with explanations that rely heavily on normal investigations or unusual symptom patterns to support a functional attribution. The same observations can be compatible with more than one diagnostic possibility. Identifying which possibility best explains an individual patient's presentation requires evidence beyond the absence of abnormalities on routine testing.
What This Means for neurosymptoms.org and FND
Our earlier examination of neurosymptoms.org questioned the evidentiary basis for presenting blurred vision, photophobia, visual snow and other disturbances within the functional neurological spectrum. The concern was not that functional visual presentations are impossible, nor that clinical examination findings are necessarily meaningless. It was whether the available evidence supports the degree of diagnostic confidence implied when such presentations are classified as functional.
The antidepressant literature introduces a concrete differential consideration. Visual snow and related disturbances have been reported in association with medications affecting serotonin reuptake, sometimes with onset during treatment, dose reduction or after discontinuation. These observations do not mean that every patient with visual snow has experienced an adverse drug reaction. Visual snow syndrome also occurs in people without relevant medication exposure, and its mechanisms remain incompletely understood.
However, the overlap means that describing a symptom as potentially functional is not sufficient to establish its origin. If a patient develops visual snow following medication exposure, the timing, dose history, changes in treatment, associated symptoms and competing explanations all deserve consideration. An FND diagnosis should not make those questions disappear.
There is also a potential treatment-related complication. Antidepressants may be prescribed to patients with FND, particularly when depression, anxiety or other coexisting conditions are present. If visual disturbances subsequently develop, clinicians must distinguish symptoms that preceded treatment from those that emerged or changed following medication exposure. Otherwise, there is a risk that a possible adverse effect could be interpreted as another manifestation of an existing diagnosis.
It is important not to overstate what has been demonstrated. The studies discussed here do not establish how frequently antidepressant-associated visual disturbances are misdiagnosed as FND, nor do they show that neurosymptoms.org has caused such misdiagnoses. What they establish is a plausible medication-related differential that should not be ignored merely because similar symptoms appear in descriptions of functional neurological presentations.
Diagnostic Overshadowing and the Problem of Premature Closure
Diagnostic overshadowing occurs when an existing diagnosis influences the interpretation of subsequent symptoms, potentially reducing attention to alternative explanations. In the context of FND, this risk becomes particularly relevant when new symptoms are assumed to belong to the established functional diagnosis without sufficient reassessment.
Medication-related visual disturbances create a particularly difficult scenario because symptoms may persist beyond the period of active treatment. A patient might present months after discontinuing an antidepressant, with normal routine ophthalmological investigations and persistent visual snow. Without a sufficiently detailed medication history, a potentially relevant exposure could be missed. Conversely, a history of antidepressant use does not itself prove that the medication caused the symptoms.
The appropriate response is neither automatic functional attribution nor automatic attribution to medication toxicity. Both conclusions require justification. The patient's clinical history, examination, relevant investigations and the limitations of available evidence must inform the differential diagnosis.
The RxISK discussion also raises the question of specialised investigations, including electroretinography and other electrophysiological assessments. Such tests can provide information about aspects of retinal or visual pathway function that may not be apparent on routine examination. However, they are not validated tests for proving antidepressant-induced visual snow, and normal results do not exclude a medication-related contribution. Their usefulness depends on the suspected pathology and the clinical circumstances.
The broader issue is one of diagnostic accountability. If visual disturbances can occur in recognised neurological conditions, ophthalmological disease, migraine, medication-associated adverse events and functional presentations, then the existence of symptom overlap should encourage careful discrimination rather than premature certainty.
The Question That Remains
There is a striking contrast between the breadth of visual symptoms discussed within the functional neurological framework and the growing literature examining medication-associated visual disturbances. The 2022 study identified a range of patient-reported visual problems associated with serotonin reuptake inhibitors. The citalopram case report described visual snow syndrome emerging after treatment despite unremarkable neurological, ophthalmological and MRI investigations. The 2026 study documented further reports of visual snow, including cases with onset after dose reduction or discontinuation and substantial persistence at the time of reporting.
None of these findings invalidates FND as a diagnostic category. Nor do they prove that antidepressants explain every overlapping presentation. They do, however, expose why diagnostic confidence must be proportionate to the evidence available for distinguishing competing causes.
For patients presenting with visual snow, palinopsia, photophobia or unexplained changes in vision, medication history is not an optional footnote. It may be central to understanding the clinical presentation. That includes medication initiation, dose changes, withdrawal and previous exposure, while recognising that temporal association alone cannot establish causality.
The question is not simply whether a visual symptom can occur in FND. It is what evidence establishes that FND is the appropriate explanation for that particular patient, rather than an adverse drug effect or another recognised condition.
When the same visual phenomena are being investigated by ophthalmologists, neurologists and pharmacovigilance researchers as possible medication-associated adverse effects, that question deserves a careful answer. Diagnostic confidence without adequate consideration of competing explanations is not a substitute for clinical reasoning.
Acknowledgment
Special thanks to @recover2renew, who shared the RxISK article New Study of Antidepressants and Vision Problems in the comments on our earlier examination of functional visual symptoms. Their contribution brought an important body of pharmacovigilance research into this discussion and helped prompt this follow-up examination. Reader contributions like this are valuable because they introduce evidence and alternative explanations that deserve to be considered alongside established diagnostic narratives.
References
- Healy D, Mangin D, Lochhead J. (2022). Development and persistence of patient-reported visual problems associated with serotonin reuptake inhibiting antidepressants. International Journal of Risk & Safety in Medicine, 33(1), 37โ47. https://doi.org/10.3233/JRS-210018
- Bobat H, Healy D, Mangin D, Lochhead J. (2026). Serotonin reuptake inhibiting antidepressants: A trigger for visual snow syndrome? International Journal of Risk & Safety in Medicine, 37(2), 242โ248. Published online 7 November 2025. https://doi.org/10.1177/09246479251394585
- Eren OE, Schรถberl F, Schankin CJ, Straube A. (2021). Visual snow syndrome after start of citalopramโnovel insights into underlying pathophysiology. European Journal of Clinical Pharmacology, 77, 271โ272. https://doi.org/10.1007/s00228-020-02996-9
- RxISK. (7 March 2022). New Study of Antidepressants and Vision Problems. Read the article.
- FND Nope. (20 November 2026). Functional Visual Symptoms: When Blurred Vision, Photophobia and Visual Snow Become FND. Read the original examination.